Download PDF
Thromb Haemost 2015; 113(05): 931-942
DOI: 10.1160/TH14-11-0982
Review Article
Schattauer GmbH

Reversal of anticoagulants: an overview of current developments

Andreas Greinacher
1   Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Germany
,
Thomas Thiele
1   Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Germany
,
Kathleen Selleng
1   Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Germany
› Author Affiliations
Further Information

Publication History

Received: 25 November 2014

Accepted after major revision: 23 February 2015

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban), and the direct thrombin inhibitor dabigatran. Especially the oral direct FXa and FIIa inhibitors overcome many of the shortcomings of heparins and vitamin K antagonists (VKAs). They are administered orally at a fixed dose; regular monitoring is not necessary; interaction with other drugs or nutrition occur less than with VKAs and they are at least as effective as VKAs for most indications tested. They are associated with about 50 % less intracranial bleeding than VKAs. Nevertheless, they are still associated with bleeding complications. Bleeding can occur spontaneously or as a result of trauma or urgent surgery. In such situations rapid reversal of the anticoagulant effect is highly desirable. For unfractionated heparin protamine, and for VKAs prothrombin complex concentrates are available as specific antidotes. Under clinical development are: for the direct and indirect FXa inhibitors a modified recombinant FXa (andexanet alpha), which lacks enzymatic activity; and for dabigatran a Fab fragment of a monoclonal antibody (idarucizumab). In addition a small molecule (aripazine) has entered phase I clinical trials, which seems to inhibit nearly all anticoagulants but VKAs and argatroban. This review summarises the current options and strategies in development to antagonise anticoagulants with a focus on the status of the development of antidotes for the oral direct FXa and FIIa inhibitors.

Keywords

New anticoagulants - antidotes - apixaban - dabigatran - rivaroxaban
 

  • References

  • 1 Daniel SB, Lovegrove MC, Shehab N. et al. Emergency Hospitalisations for Adverse Drug Events in Older Americans. N Engl J Med 2011; 365: 2002-2012.
    CrossrefPubMedGoogle Scholar
  • 2 Hansen ML, Sorensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
    PubMedGoogle Scholar
  • 3 Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005; 04: 707-721.
    CrossrefPubMedGoogle Scholar
  • 4 Eikelboom JW, Connolly SJ, Brueckmann M. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214.
    CrossrefPubMedGoogle Scholar
  • 5 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
    CrossrefPubMedGoogle Scholar
  • 6 van Es N, Coppens M, Schulman S. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
    CrossrefPubMedGoogle Scholar
  • 7 Wolzt M, Weltermann A, Nieszpaur-Los M. et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73: 439-443.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lubetsky A, Yonath H, Olchovsky D. et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-2473.
    CrossrefPubMedGoogle Scholar
  • 9 Sarode R, Milling Jr. TJ, Refaai MA. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243.
    CrossrefPubMedGoogle Scholar
  • 10 Pabinger I, Brenner B, Kalina U. et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 06: 622-631.
    CrossrefPubMedGoogle Scholar
  • 11 Kohler M, Hellstern P, Lechler E. et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80: 399-402.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
    CrossrefPubMedGoogle Scholar
  • 13 Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-1485.
    CrossrefPubMedGoogle Scholar
  • 14 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E. et al. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 2013; 08: e78696.
    CrossrefPubMedGoogle Scholar
  • 15 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Beyer-Westendorf J, Forster K, Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
    CrossrefPubMedGoogle Scholar
  • 17 Heidbuchel H, Verhamme P, Alings M. et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-2106.
    CrossrefPubMedGoogle Scholar
  • 18 Singh T, Maw TT, Henry BL. et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 08: 1533-1539.
    CrossrefPubMedGoogle Scholar
  • 19 Selleng K, Thiele T, Sümnig A. et al. Dabigatran may redistribute into the vascular compartment after hemodialysis – a case report. Hämostaseologie 2013; 33: A60 (abstract).
    PubMedGoogle Scholar
  • 20 Parasrampuria DA, Marbury T, Matsushima N. et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 2015; 113: 719-727.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
    CrossrefPubMedGoogle Scholar
  • 22 Sheffield WP, Lambourne MD, Eltringham-Smith LJ. et al. gammaT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. J Thromb Haemost 2014; 12: 1110-1115.
    CrossrefPubMedGoogle Scholar
  • 23 Hollenbach S, Lu G, DeGuzman F. et al. Andexanet-alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model – Only Andexanet Reverses Markers of fXa-mediated Anticoagulation. Circulation 2014; 130: A14657 (abstract).
    PubMedGoogle Scholar
  • 24 Crowther MA, Kitt M, McClure M. et al. Randomized double-blind, placebo controlled single ascending dose pharmacokinetik and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscl Thromb Vasc Biol. 2013. 33 05 abstract.
    Google Scholar
  • 25 Crowther MA, Kitt M, Lorenz T. et al. A phase 2 randomized, double blind placebo controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost. 2013. 11 Suppl abstract.
    Google Scholar
  • 26 Crowther MA, Mathur V, Kitt M. et al. A phase 2 randomized, double blind placebo controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alpha (PRT064445), an antidote for factor Xa inhibitors. 2013; 55th ASH annual meeting, New Orleans (abstract). https://ashconfexcom/ash/2013/webprogram/Paper56863html
    PubMedGoogle Scholar
  • 27 Crowther MA, Lu G, Conley P. et al. Sustained reversal of apixaban anticoagulation with andexanet alpha using a bolus plus infusion regimen in a phase II placebo controlled trial. Eur Heart J 2014; 35 Suppl 137 (abstract).
    PubMedGoogle Scholar
  • 28 Crowther MA, Levy G, Lu G. et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. ASH 2014; 6-9. 2014; Abstract 4269.
    PubMedGoogle Scholar
  • 29 Crowther M, Levy G, Lu G. et al. ANNEXA™-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. AHA presentation Nov 2014 2014. Session CS.3. (abstract).
    Google Scholar
  • 30 Bennett CL, Luminari S, Nissenson AR. et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408.
    CrossrefPubMedGoogle Scholar
  • 31 Li J, Yang C, Xia Y. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
    CrossrefPubMedGoogle Scholar
  • 32 Schiele F, van Ryn J, Canada K. et al. A specific antidote for dabigatran: functional and structural characterisation. Blood 2013; 121: 3554-3562.
    CrossrefPubMedGoogle Scholar
  • 33 Arellano-Rodrigo E, Lopez-Vilchez E, Molina P. et al. Idarucizumab Fully Restores Dabigatran-Induced Alterations on Platelet and Fibrin Deposition on Damaged Vessels: Studies in Vitro with Circulating Human Blood. ASH 2014; 6-912. 2014; Abstract 2878.
    PubMedGoogle Scholar
  • 34 Honickel M, Treutler S, van Ryn J. et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728-740.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Grottke O, Honickel M, van Ryn J. et al. A specific antidote to dabigatran reduces blood loss in dabigatran-and trauma-induced bleeding in pigs. J Am Coll Cardiol 2014; 63 (abstract).
    PubMedGoogle Scholar
  • 36 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Glund S, Stangier J, Schmohl M. et al. A specific antidote for dabigatran: immediate, complete, and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Presentation at AHA, Dallas, TX, USA 2013; Abstract.
    PubMedGoogle Scholar
  • 38 Glund S, Stangier J, Schmohl M. et al. Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. ASH 2014; 6-9. 12.2014; Abstract 344.
    PubMedGoogle Scholar
  • 39 van Ryn J, Schmoll M, Pillu H. et al. Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss Circulation. 2014; 130: A18403 (abstract).
    PubMedGoogle Scholar
  • 40 Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-587.
    CrossrefPubMedGoogle Scholar
  • 41 Aster RH, Curtis BR, Bougie DW. et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006; 04: 678-679.
    CrossrefPubMedGoogle Scholar
  • 42 Curtis BR, Swyers J, Divgi A. et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-2059.
    CrossrefPubMedGoogle Scholar
  • 43 Lopez-Requena A, Burrone OR, Cesco-Gaspere M. Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol 2012; 02: 159.
    PubMedGoogle Scholar
  • 44 Suciu-Foca N, Reed E, Rohowsky C. et al. Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy. Proc Natl Acad Sci USA 1983; 80: 830-834.
    CrossrefPubMedGoogle Scholar
  • 45 Schreiber AB, Couraud PO, Andre C. et al. Anti-alprenolol anti-idiotypic antibodies bind to beta-adrenergic receptors and modulate catecholamine-sensitive adenylate cyclase. Proc Natl Acad Sci USA 1980; 77: 7385-7389.
    CrossrefPubMedGoogle Scholar
  • 46 Yu Y, Cai X, Wang G. et al. Anti-idiotypic antibodies reduce efficacy of the attenuated vaccine against highly pathogenic PRRSV challenge. BMC Vet Res 2014; 10: 39.
    CrossrefPubMedGoogle Scholar
  • 47 Loeffler DA, Klaver AC, Coffey MP. Abeta anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration. Autoimmunity 2014; 1-5.
    PubMedGoogle Scholar
  • 48 Laulicht B, Bakhru S, Lee C. et al. Small molecule antidote for anticoagulants. Circulation. 2012. 126 Abstract.
    Google Scholar
  • 49 Laulicht B, Bakhru S, Jiang X. et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER 977. presented at the 24th Congress of the International Socienty on Thrombosis and Hemostasis, Amsterdam 2013; Abstract.
    PubMedGoogle Scholar
  • 50 Lu G, Kotha J, Cardenas JM. et al. In Vitro Characterisation of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent Circulation. 2014. 130 A18218 (abstract).
    Google Scholar
  • 51 Bakhru SH, Laulicht B, Jiang X. et al. Reversal of Anticoagulant-induced Bleeding in External and Internal Bleeding Models by PER977, a Small Molecule Anticoagulant Antidote. Circulation. 2014. 130 A19361 (abstract).
    Google Scholar
  • 52 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. N Engl J Med. 2014. Epub ahead of print.
    Google Scholar
  • 53 Hull RD, Pineo GF, Brant RF. et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
    CrossrefPubMedGoogle Scholar
  • 54 Lee AY, Levine MN, Baker RI. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
    CrossrefPubMedGoogle Scholar
  • 55 Palareti G. Bleeding with anticoagulant treatments. Hämostaseologie 2011; 31: 237-242.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Agnelli G, Buller HR, Cohen A. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
    CrossrefPubMedGoogle Scholar
  • 57 Agnelli G, Buller HR, Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
    CrossrefPubMedGoogle Scholar
  • 58 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
    CrossrefPubMedGoogle Scholar
  • 59 Connolly SJ, Eikelboom J, Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
    CrossrefPubMedGoogle Scholar
  • 60 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
    CrossrefPubMedGoogle Scholar
  • 61 Buller HR, Prins MH, Lensin AW. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
    CrossrefPubMedGoogle Scholar
  • 62 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
    CrossrefPubMedGoogle Scholar
  • 63 Buller HR, Decousus H, Grosso MA. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
    CrossrefPubMedGoogle Scholar
  • 64 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
    CrossrefPubMedGoogle Scholar
  • 65 Connolly SJ, Eikelboom J, Dorian P. et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013; 34: 1498-1505.
    CrossrefPubMedGoogle Scholar
  • 66 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
    CrossrefPubMedGoogle Scholar
  • 67 Schulman S, Kakkar AK, Goldhaber SZ. et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
    CrossrefPubMedGoogle Scholar
  • 68 Schulman S, Kearon C, Kakkar AK. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
    CrossrefPubMedGoogle Scholar
  • 69 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 70 Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014; 03: CD009893.
    PubMedGoogle Scholar
  • 71 Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014; 35: 1844-1855.
    CrossrefPubMedGoogle Scholar
  • 72 Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood 2012; 120: 4699-4705.
    CrossrefPubMedGoogle Scholar
  • 73 Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor–betrixaban. Expert Opin Invest Drugs 2013; 22: 1465-1472.
    CrossrefPubMedGoogle Scholar
  • 74 Chong BH, Magnani H. Danaparoid for the treatment of heparin-induced thrombocytopenie. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; pp. 478-501.
    Google Scholar
  • 75 Rice L, Beiderlinden M, Hursting MJ. Argatroban therapy in heparin-induce thrombocytopenia. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; pp. 368-399.
    Google Scholar
  • 76 Warkentin TE, Eikelboom J. Fondaparinux and other emerging anticoagulants to treat heparin induced thrombocytopenia. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; 2013. pp 502-532.
    Google Scholar